



## **Nimmune Biopharma to Participate in UBS Virtual Biotechnology Private Company Symposium**

September 16, 2024 09:00 AM Eastern Daylight Time

BLACKSBURG, Va.--(BUSINESS WIRE)--Nimmune Biopharma ("Nimmune"), a Phase 3 precision inflammation & immunology (I&I) biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics starting with ulcerative colitis and Crohn's disease, today announced that Founder and CEO Josep Bassaganya-Riera will participate in the UBS Virtual Biotechnology Private Company Symposium on September 18-19<sup>th</sup>, 2024.

The symposium provides the opportunity for leading investors to meet one-on-one and in small groups with participating companies and innovators in biotechnology.

### **About Nimmune Biopharma**

Nimmune is a late-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics. Underpinned by a discovery platform that utilizes advanced computational modeling, A.I. and bioinformatics coupled with biomedical research capabilities to pioneer innovation in immunoregulatory drug development, Nimmune's business model enables the rapid and capital-efficient clinical development of high conviction drug candidates into New Drug Application (NDA) filing and commercialization. The lead product candidate from Nimmune's discovery platform is omilancor, a wholly-owned oral, once-daily, gut-restricted, first-in-class therapeutic currently in Phase 3 development, which targets LANCL2 for Ulcerative Colitis and Crohn's disease. Phase 2 proof-of-concept data for omilancor show potential best in class efficacy and safety. For more information, please visit [www.NIMMUNEBIO.COM](http://www.NIMMUNEBIO.COM) or contact [media@nimmunebio.com](mailto:media@nimmunebio.com).

### **Contacts**

#### **Media:**

Alex Jeffrey/Jonathan Warren

Gasthalter & Co.

[Nimmune@gasthalter.com](mailto:Nimmune@gasthalter.com)

212.257.4170